BOCH
Blue Owl Capital Holdings Portfolio holdings
AUM
$310M
This Quarter Return
+12.36%
1 Year Return
+6.98%
3 Year Return
+59.66%
5 Year Return
–
10 Year Return
–
AUM
$310M
AUM Growth
+$310M
(-0.07%)
Cap. Flow
-$16.4M
Cap. Flow
% of AUM
-5.28%
Top 10 Holdings %
Top 10 Hldgs %
66.11%
Holding
86
New
13
Increased
6
Reduced
14
Closed
14
Top Buys
| 1 |
TEM
Tempus AI, Inc. Class A Common Stock
TEM
|
$5.09M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$3.71M |
| 3 |
Starwood Property Trust
STWD
|
$2.64M |
| 4 |
Dell
DELL
|
$2.56M |
| 5 |
Biomea Fusion
BMEA
|
$2.34M |
Top Sells
| 1 |
ProShares UltraPro QQQ
TQQQ
|
$10M |
| 2 |
Tango Therapeutics
TNGX
|
$6.69M |
| 3 |
ETWO
E2open Parent Holdings
ETWO
|
$3.3M |
| 4 |
Conduent
CNDT
|
$3.28M |
| 5 |
Keros Therapeutics
KROS
|
$2.71M |
Sector Composition
| 1 | Healthcare | 51.14% |
| 2 | Financials | 31.24% |
| 3 | Technology | 10.9% |
| 4 | Consumer Discretionary | 5.02% |
| 5 | Real Estate | 0.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuveen Churchill Direct Lending
NCDL
$789M
| $65.4M | 21.11% | 4,039,553 | – | – |
|
2
Blue Owl Capital
OBDC
$7.33B
| $29.3M | 9.46% | 2,045,070 | – | – |
|
3
Cullinan Oncology
CGEM
$445M
| $18M | 5.8% | 2,385,972 -50,000 | -2% | -$377K |
|
4
EverCommerce
EVCM
$2.09B
| $17.2M | 5.56% | 1,641,929 | – | – |
|
5
Tourmaline Bio
TRML
$601M
| $15.9M | 5.15% | 997,107 -40,000 | -4% | -$640K |
|
6
Larimar Therapeutics
LRMR
$310M
| $14.2M | 4.6% | 4,928,040 +150,000 | +3% | +$434K |
|
7
enGene Holdings
ENGN
$236M
| $13.6M | 4.38% | 3,728,106 +448,728 | +14% | +$1.63M |
|
|
8
Conduent
CNDT
$439M
| $11.8M | 3.8% | 4,456,848 -1,240,602 | -22% | -$3.28M |
|
9
Sagimet Biosciences
SGMT
$244M
| $10.1M | 3.27% | 1,328,351 | – | – |
|
|
10
Ultragenyx Pharmaceutical
RARE
$2.89B
| $9.28M | 3% | 255,238 +102,000 | +67% | +$3.71M |
|
11
Holley
HLLY
$490M
| $8.22M | 2.65% | 4,112,361 -1,205,679 | -23% | -$2.41M |
|
12
Civeo
CVEO
$298M
| $7.33M | 2.37% | 317,411 -30,815 | -9% | -$712K |
|
13
Compass Therapeutics
CMPX
$483M
| $6.74M | 2.17% | 2,591,525 -363,187 | -12% | -$944K |
|
14
Disc Medicine
IRON
$2.07B
| $6.47M | 2.09% | 122,260 -18,000 | -13% | -$953K |
|
|
IMA
15
ImageneBio, Inc. Common Stock
IMA
$150M
| $5.48M | 1.77% | 4,091,118 | – | – |
|
16
EyePoint Pharmaceuticals
EYPT
$797M
| $5.29M | 1.71% | 562,594 -235,000 | -29% | -$2.21M |
|
|
TEM
17
Tempus AI, Inc. Class A Common Stock
TEM
$13.2B
| $5.09M | 1.64% | +80,167 | New | +$5.09M |
|
18
Context Therapeutics
CNTX
$75.4M
| $4.85M | 1.57% | 7,407,906 +40,000 | +0.5% | +$26.2K |
|
19
Repare Therapeutics
RPTX
$71.7M
| $4.79M | 1.54% | 3,443,659 | – | – |
|
20
Mineralys Therapeutics
MLYS
$1.03B
| $4.55M | 1.47% | 335,944 +129,648 | +63% | +$1.75M |
|
|
CNTA
21
Centessa Pharmaceuticals
CNTA
$2.25B
| $4.34M | 1.4% | 330,600 +15,600 | +5% | +$205K |
|
|
22
Tango Therapeutics
TNGX
$747M
| $4.17M | 1.35% | 814,416 -1,307,236 | -62% | -$6.69M |
|
23
Eledon Pharmaceuticals
ELDN
$155M
| $3.6M | 1.16% | 1,329,912 -490,000 | -27% | -$1.33M |
|
24
Pliant Therapeutics
PLRX
$101M
| $3.44M | 1.11% | 2,969,199 | – | – |
|
25
Aquestive Therapeutics
AQST
$456M
| $3.05M | 0.98% | 920,000 | – | – |
|